Cargando…

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results

BACKGROUND: Hemophilia A is an X chromosome–linked bleeding disorder caused by the deficiency of coagulation factor VIII (FVIII). The majority of the Indian population with hemophilia A use plasma‐derived clotting factors and, in some instances, fresh frozen plasma and cryoprecipitate. Safer and mor...

Descripción completa

Detalles Bibliográficos
Autores principales:	John, M. Joseph, Chakrabarti, Prantar, Apte, Shashikant, Bhattacharyya, Maitreyee, S., Chandrakala, Hansen, Trine, Kolla, Rohan, Ross, Cecil, Seth, Tulika, Siddharthan, Neeraj, Abraham, Aby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles ‐ Hemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695559/ https://www.ncbi.nlm.nih.gov/pubmed/33313471 http://dx.doi.org/10.1002/rth2.12441

Ejemplares similares

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
por: Takedani, Hideyuki, et al.
Publicado: (2015)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
por: Wu, Runhui, et al.
Publicado: (2020)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
por: Santagostino, E, et al.
Publicado: (2015)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity
por: Wang, Michael, et al.
Publicado: (2020)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Turoctocog alfa (NovoEight®) – from design to clinical proof of concept
por: Ezban, Mirella, et al.
Publicado: (2014)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen
por: Simon, Barbara, et al.
Publicado: (2022)

Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022)

Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?
por: Pratt, Kathleen P., et al.
Publicado: (2022)

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial
por: Yaish, Hassan, et al.
Publicado: (2019)

von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
por: Oleshko, Olga, et al.
Publicado: (2023)

Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A
por: Hiramoto, Takafumi, et al.
Publicado: (2023)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021)

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
por: Eichler, Hermann, et al.
Publicado: (2023)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Global coagulation assays in hemophilia A: A comparison to conventional assays
por: Aghighi, Saman, et al.
Publicado: (2019)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
por: Takeyama, Masahiro, et al.
Publicado: (2020)

Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate
por: Schöchl, Herbert, et al.
Publicado: (2017)

Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro
por: Thomas, Kimberly A., et al.
Publicado: (2021)

Soluble protein C receptor: why?
por: Geiger, Margarethe
Publicado: (2008)

Screening platelet function in blood donors
por: Pedini, Pascal, et al.
Publicado: (2022)

Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA‐02 and FORMA‐04 clinical trials
por: Khayat, Claudia Djambas, et al.
Publicado: (2022)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
por: Lentz, Steven R., et al.
Publicado: (2022)

Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR
por: Manderstedt, Eric, et al.
Publicado: (2020)

Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research
por: Dover, Saunya, et al.
Publicado: (2020)

Patient selection for hemophilia gene therapy: Real‐life data from a single center
por: Krumb, Evelien, et al.
Publicado: (2021)

An overview of turoctocog alfa pegol (N8‐GP; ESPEROCT(®)) assay performance: Implications for postadministration monitoring
por: Ezban, Mirella, et al.
Publicado: (2019)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
por: Shrestha, Anshu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9o9pppic0b65n7fdd9sag4otg8